Your browser doesn't support javascript.
loading
IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis.
Balak, Deepak M W; van Doorn, Martijn B A; Arbeit, Robert D; Rijneveld, Rianne; Klaassen, Erica; Sullivan, Tim; Brevard, Julie; Thio, Hok Bing; Prens, Errol P; Burggraaf, Jacobus; Rissmann, Robert.
Afiliação
  • Balak DM; Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • van Doorn MB; Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Arbeit RD; Idera Pharmaceuticals, Inc., Cambridge, MA, USA.
  • Rijneveld R; Centre for Human Drug Research, Leiden, The Netherlands.
  • Klaassen E; Centre for Human Drug Research, Leiden, The Netherlands.
  • Sullivan T; Idera Pharmaceuticals, Inc., Cambridge, MA, USA.
  • Brevard J; Idera Pharmaceuticals, Inc., Cambridge, MA, USA.
  • Thio HB; Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Prens EP; Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Burggraaf J; Centre for Human Drug Research, Leiden, The Netherlands.
  • Rissmann R; Centre for Human Drug Research, Leiden, The Netherlands. Electronic address: rrissmann@chdr.nl.
Clin Immunol ; 174: 63-72, 2017 01.
Article em En | MEDLINE | ID: mdl-27876460

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Receptor Toll-Like 9 / Receptor 7 Toll-Like / Receptor 8 Toll-Like Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Receptor Toll-Like 9 / Receptor 7 Toll-Like / Receptor 8 Toll-Like Idioma: En Ano de publicação: 2017 Tipo de documento: Article